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SUMMARY
Objective: Kidney transplantation is the best option for patients with end-stage renal 
disease. This study evaluated the profile of cystatin C (CysC), interleukin 2 (IL-2), IL-
6, and tumor necrosis factor-α (TNF-α) as inflammatory markers in 23 living donor 
kidney transplant recipients. Methods: A descriptive, analytical and prospective study 
was conducted between January 1st, 2007 and June 30th, 2008 on 23 living donor kidney 
transplant recipients. The biomarkers were evaluated before and 30 and 180 days after 
transplantation. Results: The mean age of the patients was 34.3 years (± 11.7), females 
(52%) and non-whites (61%). Significant difference was found in cystatin C and cre-
atinine before and 30 days after transplantation (p < 0.0001) and before and 180 days 
after transplantation (p  <  0.0001). There was a significant difference in IL-2 between 
30 and 180 days post-transplant (p  =  0.0418) and in TNF-α between pre-transplant 
and 30 days post-transplant (p = 0.0001). A negative correlation was observed between 
cystatin C and TNF-α at pre-transplant and between cystatin C and IL-6 at 180 days 
post-transplant. Comparison of biopsied and non-biopsied patients showed a significant 
difference in creatinine and cystatin C at 30 and 180 days post-transplant in biopsied 
patients. Conclusion: Our results showed no significant correlations between CysC, 
IL-2, IL-6 and TNF-α levels in kidney transplant recipients at short-term follow-up. 
Moreover, CysC levels were very similar to creatinine levels in contrast to other inflam-
matory markers studied in biopsied and non-biopsied patients. Further studies are im-
portant to evaluate the long-term profile of these markers.
Keywords: Cystatin C; creatinine; biological markers; graft rejection; kidney trans-
plantation.
Study conducted at Hospital 
Universitário Presidente Dutra, 
Universidade Federal do 
Maranhão, São Luiz, MA, Brazil
Submitted on: 12/09/2010
Approved on: 03/22/2011
Correspondence to: 
José Ribamar Lima
Residencial Turquesa, n° 29 – Anil
São Luís – MA
CEP: 65060-770
Phone: (98) 9976-6025
ribamarjr@hotmail.com; 
jvlsalgado@yahoo.com.br
Conflict of interest: None.
Cystatin C and inflammatory markers in kidney transplant recipients
JOSÉ RIBAMAR LIMA1, JOÃO VICTOR SALGADO2, TERESA CRISTINA FERREIRA3, MARIA INÊS OLIVEIRA4, ALCIONE MIRANDA DOS SANTOS5,  
NATALINO SALGADO FILHO6
1 Ph.D. Student in Health Sciences, Universidade de Brasília; Nephrology Service, Hospital Universitário, Universidade Federal do Maranhão, São Luís, MA, Brazil
2 M.Sc. in Health Sciences, Universidade de Brasília; Clinical Analyses Service, Hospital Universitário, Universidade Federal do Maranhão, São Luís, MA, Brazil
3 Ph.D. Student in Nephrology, Universidade Federal de Juiz de Fora; Nephrology and Renal Transplant Division, Hospital Universitário, Universidade Federal do Maranhão, São Luís, 
MA, Brazil
4 M.Sc. in Health Sciences,Universidade Federal do Maranhão; Nephrology and Renal Transplant Division, Hospital Universitário, Universidade Federal do Maranhão, São Luís, 
MA, Brazil
5 Ph.D. in Production Engineering, Universidade Federal do Rio de Janeiro; Public Health Department, Universidade Federal do Maranhão, São Luís, MA, Brazil
6 Ph.D. in Nephrology, UNIFESP; Nephrology and Renal Transplant Division, Hospital Universitário, Universidade Federal do Maranhão, São Luís, MA, Brazil
Open access under CC BY-NC-ND license.
JOSÉ RIBAMAR LIMA ET AL.
342 Rev Assoc Med Bras 2011; 57(3):341-346
INTRODUCTION
A kidney transplant is the best therapeutic and reha-
bilitation option for patients with end-stage renal dis-
ease (ESRD) since it provides a better quality of life and 
life expectancy to the patient than dialysis. However, 
chronic graft dysfunction is an important cause of renal 
graft loss and the treatment of this condition is nonspe-
cific in view of its multifactorial etiology. In this setting, 
for the management of kidney transplant recipients, it 
is essential to avoid or delay the progression of chronic 
graft dysfunction by means of its prevention and an 
early diagnosis1. 
Ischemia-reperfusion injury, which occurs during 
the removal and implantation of the renal graft, involves 
immunological and non-immunological mechanisms 
associated with inflammation, whose mediators include 
complement, procoagulant factors, cytokines, and fibri-
nolytic agents2. Acute inflammation is the response of tis-
sue to injury and is characterized by an increase in blood 
flow and vascular permeability as a result of the accumu-
lation of fluids, leukocytes and inflammatory mediators 
such as cytokines. During the chronic phase, inflamma-
tion is characterized by the development of a humoral 
and cellular immune response3.
Acute renal graft rejection is a common event during 
the early and late post-transplant period and a kidney bi-
opsy is the gold standard for its diagnosis. Acute rejection 
is characterized by endothelitis/arteritis and tubulointer-
stitial inflammation4. Evidence suggests that persistent 
inflammation and oxidative stress (the formation of re-
active oxygen species) start early during the process of 
renal function decline. Recently there has been interest in 
the potential value of pretransplant inflammatory mark-
ers as predictors of acute rejection and graft loss in adult 
kidney transplant patients5,6. 
Inflammation directly associated with atherosclerosis 
may influence graft loss and cardiovascular disease. Sev-
eral studies have demonstrated that inflammatory mark-
ers such as interleukin 2 (IL-2), IL-6 and tumor necro-
sis factor alpha (TNF-α) are associated with episodes of 
acute rejection7. However, these markers have not always 
been useful in distinguishing between rejection and in-
fection or tubular damage. In addition, cystatin C, which 
is known to be a sensitive marker of small reductions 
in renal function7, has shown linear associations with 
inflammatory markers, also suggesting adverse physio-
pathological consequences8-10.
More detailed studies investigating markers that 
could be used for the early and non-invasive evaluation 
of renal damage are necessary. Therefore, the objective of 
the present study was to evaluate the short-term profile 
of cystatin C, IL-2, IL-6 and TNF-α in kidney transplant 
recipients and the potential role of them as predictors of 
early renal graft dysfunction.
METHODS
A descriptive, analytical and prospective study was con-
ducted between January 1st, 2007 and June 30th, 2008 on 
23 kidney transplant patients seen at the transplant unit of 
Hospital Universitário, Universidade Federal do Maranhão 
(HUUFMA). Patients ranging in age from 18 to 60 years 
who received a kidney transplant from a living donor and 
who signed the free informed consent form were included 
in the study. The hospitalized patients were prepared for 
transplantation by the medical team, with the evaluation 
of serology, hepatic, renal and cardiac function, imaging 
exams, HLA compatibility, and crossmatching. The fol-
lowing triple immunosuppression schemes were used: 1) 
tacrolimus, mycophenolate mofetil, and prednisone; 2) cy-
closporin, azathioprine, and prednisone. 
After the selection procedures and admission of the 
patients for transplantation, data collection was started by 
signing the free informed consent form and subsequent 
application of a clinical-laboratory questionnaire. The 
biomarkers studied were measured before and 30 and 180 
days after kidney transplantation. Blood was collected in-
dividually at the transplant unit by specialized technicians 
and the samples were identified, properly stored, and sent 
for laboratory analysis. The biomarkers were compared 
between patients submitted to graft biopsy and those not 
submitted to this procedure.
Cystatin C was measured in serum samples by neph-
elometry using the BN II ProSpec equipment and reagents 
(Siemens) according to manufacturer instructions. Serum 
samples were obtained by coagulation and centrifuga-
tion of whole blood at 3,500 rpm for 15 min. Serum lev-
els of IL-2, IL-6 and TNF-α were measured using human 
TiterZyme enzyme immunoassay (EIA) kits. The refer-
ence values provided by the manufacturer were adopted: 
2.0 pg/mL for IL-2, up to 6.01 pg/mL for IL-6, and up to 
8.43 pg/mL for TNF-α.
The quantitative variables are reported as the mean and 
standard deviation or median, and qualitative variables are 
expressed as frequency and percentage. The Shapiro-Wilk 
test was used to determine whether the quantitative vari-
ables showed a normal distribution. Since the variables were 
not normally distributed, Friedman’s test was used to com-
pare the markers between the different time points. Spear-
man’s correlation coe cient was calculated to determine 
which markers were correlated with cystatin C. A level of 
significance of 5% was adopted. Statistical analysis was per-
formed using the STATA 9.0 program. The study was ap-
proved by the Ethics Committee of Hospital Universitário, 
Universidade Federal do Maranhão (protocol 322/6).
RESULTS
The mean age of the patients was 34.3 years (± 11.7). There 
was a predominance of females (52%) and  non-white 
(61%). The mean weight and height of the patients, dia-
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stolic and systolic blood pressure and hemoglobin, albu-
min, phosphorus and creatinine levels, as well as underly-
ing diseases, are shown in Table 1.
Comparison of the biomarkers between the different 
sampling times showed a significant difference in plasma 
creatinine and cystatin C between admission and 30 days 
post-transplant (p < 0.0001), and between admission and 
180 days post-transplant (p < 0.0001). On the other hand, 
a significant difference in IL-2 was only observed be-
tween 30 and 180 days post-transplant (p = 0.0418) and 
in TNF-α between admission and 30 days post-transplant 
(p = 0.0001), whereas there was no significant difference 
in IL-6 (Table 2).
Analysis of the correlation between cystatin C and 
the other markers by Spearman’s test showed a significant 
negative correlation between cystatin C and TNF-α at ad-
Variable
Age (years) 34.3 ± 11.7
Gender
Female/male (%) 12/11 (52/48)
Race
Non-white/white (%) 14/9 (61/39)
Weight (kg) 55.2 ± 14
Height (cm) 158 ± 0.1
Diastolic pressure (mmHg) 133 ± 21.6
Systolic pressure (mmHg) 88 ± 15.6
Hemoglobin (g/dL) 11.7 ± 1.9
Albumin (mg/dL) 4.1 ± 0.5
Phosphorus (mg/dL) 6.2 ± 1.7
Creatinine (mg/dL) 8.9 ± 4.1
Underlying disease
Non-glomerular/glomerular (%) 12/11 (52/48)
Table 1 – Demographic and clinical characteristics at 
admission of the kidney transplant population studied 
(n = 23)
Biomarkers 
Sampling time
Admission 30 days 180 days p
Creatinine (mg/dL) 8.97 ± 4.1 1.5 ± 1.2 1.6 ± 0.7 < 0.0001a
Cystatin C (mg/dL) 6.59 ± 1.4 1.6 ± 0.85 1.39 ± 0.72 < 0.0001a
IL-2 (pg/mL) 13.47 ± 29.1 8.7 ± 19.0 4.93 ± 7.8 0.0418b
IL- 6 (pg/mL) 29.87 ± 51.7 24.50 ± 50.7 50.61 ± 130.8 0.7457
TNF-_ (pg/mL) 13.4 ± 7.2 4.96 ± 3.5 10.35 ± 13.1 0.0001c
a Signicant difference (at the 5% level) between admission and 30 days post-transplant and between admission and 180 days post-transplant. 
b Signicant difference (at the 5% level) between 30 and 180 days post-transplant. c Signicant difference (at the 5% level) between admission 
and 30 days post-transplant.
Table 2 – Mean and standard deviation of the biomarkers at admission and 30 and 180 days after transplantation
mission (r = -0.44) and between cystatin C and IL-6 at 180 
days post-transplant (r = -0.38). 
A graft biopsy was obtained from eight of the 23 patients 
because of elevated serum levels of creatinine in six and el-
evated proteinuria in two. A normal biopsy result was ob-
tained in two patients, three presented acute drug nephro-
toxicity, recurrence of the underlying disease was observed 
in two, and one patient had a confirmatory result of cell re-
jection. The immunosuppression scheme used was tacroli-
mus, mycophenolate mofetil and prednisone in 19 patients, 
and cyclosporin, azathioprine and prednisone in four.
The mean plasma concentrations of the biomark-
ers were compared at admission and 30 and 180 days 
post-transplant between biopsied (n  =  8) and non-bi-
opsied (n  =  15) patients. A significant difference was 
only observed for serum creatinine and cystatin C at 30 
days post-transplant (p = 0.0040 vs p = 0.0417) and 180 days 
post-transplant (p  =  0.0077 vs p  =  0.0137) (Table  3). 
No significant differences were observed in pretransplant 
serum levels of cystatin C, IL-2, IL-6 or TNF-α between 
biopsied (n = 8) and non-biopsied patients (n = 15).
DISCUSSION
The mean age of the patients studied was 34.3 years 
(±  11.7), in agreement with the literature9,11-13. Bohler et 
al.14 investigated cofactors that potentially influence the 
expression of immunological biomarkers, exploring the 
proliferation and activation of T cells (expression of CD25 
and CD17) and the production of cytokines by lympho-
cytes (IL-2 and TNF-α) in healthy volunteers, dialysis pa-
tients and stable kidney transplant patients receiving stan-
dard immunosuppressive therapy. The authors observed a 
positive correlation between age and TNF-α expression in 
all three populations. In contrast, the expression of IL-2 
was positively correlated with age only in healthy volun-
teers and kidney transplant patients, indicating that age 
exerts diverse effects on the adaptive immune system, 
which modulates the immunogenicity of donor organs in 
terms of the recipient’s capacity to reject the organ. The 
same authors also demonstrated a reduction of T cell 
function in kidney transplant patients when compared 
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to healthy volunteers and dialysis patients, as we all as an 
increase of IL-2 expression in dialysis patients when com-
pared to healthy volunteers. Similarly, Fijter et al.15 showed 
that kidneys from elderly donors provoke an increase in 
immunogenicity associated with a higher susceptibility 
to graft loss due to rejection of the transplant and chronic 
graft nephropathy.
According to Rostaing et al.16, the dialysis membrane 
may eventually stimulate T cells and different dialysis 
membranes have different abilities to stimulate the expres-
sion of IL-2. In contrast, van Riemsdijk-Van Overbeeke et 
al.17 found that the expression of IL-2 and IL-2 receptor on 
T cells is unaffected in dialysis patients. In agreement with 
the findings of Rostaing et al.16, the present study also ob-
served elevated IL-2 levels after dialysis. The induction of 
the proinflammatory cytokine IL-2 during dialysis might 
be unfavorable for the short-term outcome after kidney 
transplantation since it sensitizes the recipient’s immune 
system to the graft14.
In the current study, patients originating from hemo-
dialysis presented elevated serum levels of IL-2, IL-6 and 
TNF-α. These results agree with Rysz et al.18, in terms of 
serum IL-6 and TNF-α levels but not IL-2. Rysz et al.18 
studied patients on regular hemodialysis therapy at dif-
ferent times (20, 60 and 240  min) of a single session in 
order to compare the serum levels of a panel of inflamma-
tory cytokines (IL-1, IL-2, IL-6, IL-8, and TNF-α) with 
C-reactive protein (CRP) using healthy subjects as con-
trols. The authors observed a higher CRP concentration in 
hemodialysis patients when compared to healthy controls. 
The concentrations of IL-1, IL-6, IL-8 and TNF-α were 
increased, whereas serum IL-2 levels remained unchanged 
during the hemodialysis session.
In the present study, we found increased serum concen-
trations of creatinine, cystatin C, IL-2, IL-6 and  TNF-α at 
admission  period.  After transplantation, there was a de-
crease in creatinine, cystatin C and IL-2 levels, whereas 
IL-6 and    TNF-α remained elevated. This fact indicates 
that a kidney transplant has an important impact on these 
markers, which is more pronounced in the case of some 
markers and less pronounced in the case of others. One 
interesting finding was the gradual decline in IL-2 levels at 
30 and 180 days post-transplant, which was not observed 
for IL-6 and TNF-α whose levels were found to be reduced 
at 30 days and increased at 180 days post-transplant. 
The present results showed a non-significant reduction 
in serum IL-6 levels, with levels above normal, at 30 days 
post-transplant and higher levels at 6 months post-trans-
plant. These findings disagree with Simmons et al.19, but 
are similar when compared to the reduced serum levels of 
TNF-α 30 days post-transplant. Simmons et al.19 studied 
19 patients undergoing living donor kidney transplanta-
tion at different time points: 1 week before transplantation 
and 1 week and 2 months after transplantation. The follow-
ing biomarkers of inflammation and oxidative stress were 
assayed: CRP, IL-6, IL-10, TNF-α, protein-associated car-
bonyl content, and F2 isoprostanes. The authors observed 
that pretransplant levels of the proinflammatory proteins 
IL-6, TNF-α and CRP, as well as the oxidative stress mark-
ers plasma protein carbonyl and F2 isoprostanes, were sig-
nificantly elevated when compared to control. In addition, 
there was a rapid and significant decline in all of these bio-
markers after transplantation that persisted for 2 months, 
indicating the restoration of renal function characterized 
by a reduction of chronic inflammation and oxidative 
stress associated with uremia. 
Cueto-Manzano et al.9 compared serum levels of CRP, 
IL-6 and TNF-α in 37 patients before and after kidney 
transplantation. CRP levels tended to be higher in recipi-
ents than in donors but this difference was not statistically 
significant, with the observation of a significant reduc-
tion of CRP concentration in recipients immediately after 
transplantation. Pre-transplant serum levels of TNF-α and 
IL-6 were significantly higher in recipients than in donors. 
After an initial reduction at 6 months post-transplant, 
TNF-α and IL-6 levels increased even further in recipients 
at 12 and 18 months. In contrast to the results reported 
by Cueto-Manzano et al.9, the present study found no re-
duction of TNF-α or IL-6 levels in recipients but rather an 
increase of these markers at 6 months post-transplant.
Table 3 – Mean and standard deviation of the biomarkers in biopsied (n =8) and non-biopsied patients (n = 15) 30 and 180 
days after transplantation
  30 days after transplantation   180 days after transplantation  
  Biopsied Non-biopsied p Biopsied Non-biopsied p
Creatinine 2.29 ± 4.9 1.12 ± 0.3 0.0040* 2.1 ± 0.9 1.3 ± 0.3 0.0077*
Cystatin C 2.11 ± 1.2 1.32 ± 0.3 0.0417* 1.83 ± 1.0 1.15 ± 0.2 0.0137*
IL-2 15.68 ± 32.1 4.97 ± 2.4 0.5444 8.42 ± 13.0 3.07 ± 0.3 0.5212
IL-6 34.72 ± 63.9 19.05 ± 43.7 0.6055 91.21 ± 208.5 28.95 ± 60.8 0.9484
TNF-_ 5.96 ± 4.5 4.41 ± 2.8 0.8399 16.05 ± 21.0 7.30 ± 4.5 0.8461
* Signicant at the 5% level.
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Comparison of serum creatinine and cystatin C levels 
between the different sampling times showed a significant 
reduction in the two markers between admission and 30 
days post-transplant (p < 0.0001) and between admission 
and 180 days post-transplant (p < 0.0001), in agreement 
with the literature20-22. This similarity in the creatinine and 
cystatin C profiles calls attention because mean creatinine 
levels tend to increase (1.6 mg/dL) in the sixth post-trans-
plant month when compared to 30 days post-transplant 
(1.5 mg/dL), whereas the opposite is observed for cystatin 
C (1.6 mg/dL at 30 days post-transplant and 1.39 mg/dL 
at 180 days). In the study of Harada et al.23, one of the risk 
factors associated with graft loss was renal function in the 
sixth post-transplant month evaluated based on creatinine 
using a level > 1.5 mg/dL as the criterion cut-off.
In a study performed by Geramizadeh et al.24, there was 
a progressive decline in serum creatinine levels during the 
first 5 days post transplant, but the levels of serum cystatin 
C did not decrease in these days. There was also a signifi-
cant correlation with serum cys tatin C levels and steroid 
dose in the first 5 days post transplant (r  =  0.625). This 
study suggests that during the first week, after transplanta-
tion, serum creatinine is still a good marker to assess the 
renal function. According to the authors, the level of cys-
tatin C is dependent on high steroid dose in the first week 
post renal transplantation and should be used as a marker 
of renal function afterwards.
Karczewski et al.10, studying 44 kidney transplant pa-
tients with and without rejection, evaluated serum con-
centrations of IL-2, IL-4, IL-5, IL-10, IFN-fl, and TNF-α in 
samples collected one day before and 2, 7, 14 and 30 days 
after transplantation.
Eleven of these patients developed episodes of acute 
rejection, which were associated with higher pretransplant 
serum levels of IFN-fl and IL-10. No significant difference 
in plasma levels of IL-2, IL-4, IL-5 or TNF-α were observed 
between the two groups.
Similar to the study of Karczewski et al.10, no significant 
difference in serum IL-2 or TNF-α levels was observed at 
admission and at 30 days post-transplant between biop-
sied and non-biopsied patients. However, only 4% (1/23) 
of the patients presented graft rejection, whereas this prev-
alence was 25% (11/44) in the study of Karczewski et al.10.
Ozdemir et al.12 also studied the demographic, clini-
cal and laboratory data of 141 kidney transplant recipi-
ents over a period of 5 years. The patients were divided 
into three groups based on serum CRP concentration: 
normal, intermittently high and consistently high. Renal 
graft survival rates were 90%, 72.6% and 11.1% in these 
groups, respectively. In addition, Cox regression analysis 
revealed that acute rejection, advanced recipient age and 
consistently high serum concentrations of CRP were asso-
ciated with an elevated risk of renal graft loss. Intermittent 
elevations in serum CRP levels were not associated with 
an increased risk of graft loss. The authors concluded that 
consistently high post-transplant concentrations of CRP 
have a high negative predictive value for graft survival. 
According to the authors, kidney transplant recipients 
presenting an ongoing inflammatory process during the 
5-year post-transplant period require additional efforts 
to control inflammation and to prolong graft survival. 
These considerations suggest the long-term investigation 
of other inflammatory markers which, if also consistently 
elevated, may compromise renal graft survival.
Recent studies demonstrate that novel kidney markers 
such as cystatin C, IL-18, kidney injury molecule 1, and 
neutrophil gelatinase-associated lipocalin serve as more 
accurate markers for acute kidney injury as compared with 
the more traditional marker, creatinine. Each individual 
kidney marker possesses its own strengths and weaknesses 
in determining the onset and severity of acute kidney in-
jury. However, in combination, a panel of kidney markers 
may serve as powerful tools in diagnosing kidney injury 
with high accuracy25.
Some limitations of the present study should be men-
tioned. The inclusion criteria did not permit to obtain a 
larger sample of patients. Serum samples were not obtained 
from donors at transplantation. Inflammation markers 
(cystatin C, IL-2, IL-6, and TNF-α) were investigated over 
a short period of time (180 days) and not during episodes 
of graft dysfunction.
CONCLUSION
Numerous studies are investigating markers of early renal 
graft dysfunction that would be able to detect the onset 
of renal leukocyte infiltration since the best marker has 
yet to be defined. The current study showed no significant 
correlations between CysC, IL-2, IL-6 and TNF-α serum 
levels in kidney transplant recipients at short-term follow-
up. Moreover, CysC levels were very similar to creatinine 
levels in contrast to other inflammatory markers studied 
in biopsied and non-biopsied patients. When compared 
to the other inflammatory biomarkers, serum creatinine 
and cystatin C seem to be good predictors of early graft 
dysfunction in transplant patients and can be used to es-
tablish actions that prevent functional loss of the graft. 
Our results showed an impact of kidney transplant on the 
concentrations of the inflammatory markers studied, with 
IL-2, IL-6 and TNF-α representing an option for the long-
term monitoring of renal grafts. However, further studies 
evaluating pre- and post-transplant inflammatory markers 
are necessary to confirm the findings of the present study.
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